Keynote-224. Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: Pembrolizumab was administered to patients at 200 mg every 3 weeks until unacceptable toxicity or confirmed disease progression.
Pembrolizumab active and well tolerated in pretreated advanced hepatocellular carcinoma Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: